GENEVA, March 8 (Reuters) - Waiving intellectual property
rights will not be enough to resolve COVID-19 vaccine access
issues, the developers of the Oxford/Astrazeneca and the
Pfizer/BioNTech vaccines said on Monday, ahead of a meeting on
the topic at the World Trade Organization this week.
 urn:newsml:reuters.com:*:nL5N2L22NF
    "I don't think just making IP fully available goes anywhere
close to solving the problem...," said the University of Oxford
professor Sarah Gilbert at a World Health Organization virtual
press conference.
    BioNTech's Chief Medical Officer Dr Özlem Türeci said at the
same briefing: "Patents are one thing, but there are so many
other things we have to ensure."

 (Reporting by Emma Farge, Silke Koltrowitz and Toby Chopra;
Editing by Hugh Lawson)
 ((emma.farge@thomsonreuters.com;))